F or many years, atherosclerosis was thought to be a slow process of continuous growth of lesions. It was generally believed to be irreversible and to cause clinical symptoms when the sheer size of the plaque obstructed blood flow. This view has been completely changed during the last decade. Early studies of primates showed that whereas a high-cholesterol diet induced atherosclerotic lesions, a switch to low-fat diet led to regression of plaques within a few months. 1 These findings revealed that the atherosclerotic process is much more dynamic than had previously been anticipated. When modern lipid-lowering drugs became available, patients with coronary heart disease were treated aggressively and their coronary circulation examined by repeated angiographies. 2 Again, some plaques were found to regress on treatment. However, clinical studies showed more remarkable effects on clinical events than on the degree of stenosis, 2 suggesting that regression therapy acts to modify the composition of the plaque as well as reducing its size.
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Analysis in experimental models have confirmed and extended these conclusions. When hypercholesterolemic rabbits were switched to a lipid-lowering diet, the composition of the lesions changed rapidly into a more stable phenotype. 3, 4 Smooth muscle cells accumulated and collagen increased whereas inflammation waned and signs of proteolytic and prothrombotic activity were reduced. All of these phenomena reflect the cellular dynamics of the atherosclerotic plaque, where metabolic changes impact on cell accumulation, differentiation, and gene expression. Whereas hyperlipidemic conditions promote the formation of large, vulnerable plaques with activated immune cells, intense inflammation, proteolysis, and prothrombotic conditions, lipid lowering can reverse the process. Inflammation cools down, proteases and prothrombotic factors disappear, and the smooth muscle cells form a stable cap stabilized by collagen bundles.
The careful characterization of the regression process in experimental animals has been of great importance for understanding and developing therapeutic principles in man. However, the possibilities to follow the regression-or progression-of individual lesions in patients are still very limited. Angiography remains a golden standard but does not really tell us anything about the composition of the lesions. Indeed, angiography portrays what is not there by depicting the lumen rather than the artery wall. Among other imaging modalities, ultrasonography has undergone a rapid development and can now be used to measure the size of lesions. It is even possible to identify lipid core regions, particularly when intravascular ultrasound (IVUS) is used. However, this technology is technically demanding and invasive, and conventional ultrasonography is hampered by limited resolution. The same is still true for MRI, although rapid progress is taking place and high resolution with chemical selectivity may become a reality within a few years. Unfortunately, even such high-resolution methods cannot provide information about the molecular dynamics that characterize atherosclerotic events. The new study uses radiolabeled antibodies to detect uptake of oxidized molecules in lesions. Such antibodies accumulate in lesions of progressive disease but do not label lesions undergoing regression. Although the new study used ex vivo detection of 125 I-labeled antibodies, the authors have previously demonstrated that such antibodies can be detected also by gamma camera technology. 6 This suggests that it may be possible to develop scintigraphic technology for monitoring progression/regression of atherosclerotic plaques in patients.
The molecular marker for disease activity used in the new study reflects oxidative activity. Lipid peroxidation generates malondialdehyde, which binds to and may crosslink ⑀-amino groups of lysines in polypeptide chains. Malondialdehyde adducts are formed on the apolipoprotein B moiety during oxidation of LDL and leads to rapid uptake through scavenger receptors on macrophages and other cells. 7 The MDA2 antibody used by Torzewski et al recognizes a small epitope consisting of malondialdehyde-lysine; it is common in oxidized LDL but can also occur in other proteins exposed to products of lipid peroxidation. In vivo uptake of MDA2 therefore probably presents an integrated view of oxidative activity and accumulation of oxidized LDL. This, in turn, reflects the presence of activated macrophages, which makes MDA2 an attractive tool for identifying plaques with high inflammatory activity. Indeed, MDA2-positive lesions were found to contain more macrophages, fewer smooth muscle cells, and less collagen than MDA2-negative ones. This clearly suggests that MDA2 detects vulnerable but not stable lesions.
The finding that antibodies reacting with oxidized LDL relatively selectively recognize active vulnerable lesions suggests an important role for LDL oxidation in disease devel-opment. It adds to strong evidence for LDL oxidation being a trigger for intracellular cholesterol accumulation, 8 initiating autoimmune reactions by breaking T-cell tolerance 9 and ligating natural antibodies, 10 and by promoting endothelial cell activation. 11 Several clinical studies have shown that circulating levels of oxidized LDL 12 as well as titers of antibodies to such particles 13, 14 correlate to progression of coronary heart disease and other manifestations of atherosclerosis. It will now be important to determine whether the total level of LDL oxidation, or merely its accumulation in plaques, reflects progressive atherosclerotic disease. In other words, is there a future role for MDA2 and similar antibodies in immunochemical serum assays of risk markers as well as in scintigraphic imaging of lesions?
There is now solid documentation, from the present study and several previous ones, that oxidation-specific antibodies accumulate to a greater extent in active vulnerable plaques than in regressing stable ones. The present study suggests that imaging of antibody accumulation can be used to identify vulnerable plaques and to monitor the effect of stabilizing therapy. Based on these exciting observations, it is now time to test the new tools and principles for in vivo imaging, first in live animals and later, hopefully, in patients.
